ClinicalTrials.gg
RecruitingNCT06600932Updated Nov 20, 2026

Evaluation of TMS Visual Outcome

An interventional study of TMS and control group in Cataract Surgery Experience, sponsored by Shanghai High Myopia Study Group. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai High Myopia Study Group · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 20, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Cataract with a site in China — 39 open to participants now, 49 under way, none of them phase 3. Cataract · China.

Planned enrollment
28th of 111
200 · median 90
Started
2025
with 14 others
No phase
104 of 184
19 open now
Primary completion
2027-10
later than 36 of 48 live
Registered
143rd of 184
by date

Among the 184 studies in Cataract with a site in China, this one is the 28th largest by planned enrollment of the 111 interventional ones that give a count, is one of 15 that started in 2025, is one of 104 with no phase, reaches primary completion later than 36 of the 48 other live ones, and was the 143rd registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

39 of the 184 studies in Cataract with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Cataract with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients after cataract surgery. The main question it aims to answer is:

  • Does TMS improve the visual outcome in patients after cataract surgery? Researchers will compare TMS to the sham-controlled treatment (exposure to recorded sounds of pulses without real magnetic stimulation) to see if TMS works to improve the visual outcomes of patients after cataract surgery.

Participants will

  • Undergo TMS treatment or a sham-controlled treatment for consecutive 5 days.
  • Visit the clinic once every 2 weeks for checkups and tests.
03

Conditions studied

  • Cataract Surgery Experience

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post cataract surgery
  • Best-corrected visual acuity less than 0.1logMAR

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment;
  • Diagnosed with significant opacity of refractive media that affects observation of visual function;
  • History of epileptic seizures;
  • Long term use of psychotropic drugs;
  • Metal implants in the body.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    TMS

    TMS treatment indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

    Procedure: TMS

  • Sham comparator
    Control

    The sham group will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.

    Procedure: control group

Interventions

  • ProcedureTMS

    TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

  • Procedurecontrol group

    The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.

06

What researchers measure

Primary outcomes

  1. Visual acuity

    Time frame: From enrollment to the end of treatment at 2 weeks

Secondary outcomes

  1. Visual field

    Time frame: From enrollment to the end of treatment at 2 weeks

Other outcomes

  1. Visual quality

    Include objective visual quality (contrast sensitivity) and subjective visual quality (visual function questionnaire score).

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 24 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Oct 2024 → Oct 2025, primary completion Oct 2025 → Oct 2027 and completion Oct 2026 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2024
First posted
Sep 19, 2024
StartActual
Oct 1, 2025was Oct 2024
Primary completionEst.
Oct 2027was Oct 2025
CompletionEst.
Oct 2028was Oct 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Eye and Ear, Nose Throat Hospital of Fudan University · Shanghai, China
Show 1 removed
  • Eye and Ear, Nose Throat Hospital of Fudan University · Shanghai, China
Nov 20, 2026
Start date
Oct 2024→Oct 1, 2025 (actual)
Nov 20, 2026
Primary completion
Oct 2025→Oct 2027
Nov 20, 2026
Study completion
Oct 2026→Oct 2028
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Eye and Ear, Nose Throat Hospital of Fudan University · Shanghai, China
    Show 1 removed
    • Eye and Ear, Nose Throat Hospital of Fudan University · Shanghai, China
    Start date Oct 2024→Oct 1, 2025 (now actual)
    Primary completion Oct 2025→Oct 2027
    Study completion Oct 2026→Oct 2028
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06600932
Lead sponsor
Shanghai High Myopia Study Group
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 1, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Xiangjia Zhu
Contact
zhuxiangjia1982@126.com
0086+02164377134
Xiangjia Zhu
study chair · Eye & ENT Hospital of Fudan University
Jiaqi Meng
principal investigator · Eye & ENT Hospital of Fudan University
Yinglei Zhang
principal investigator · Eye & ENT Hospital of Fudan University
Yating Tang
principal investigator · Eye & ENT Hospital of Fudan University
Xin Liu
principal investigator · Eye & ENT Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion